Inhibrx Pre-Tax Profit Margin 2020-2022 | INBX
Inhibrx pre-tax profit margin from 2020 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Inhibrx Pre-Tax Profit Margin Historical Data |
Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
2022-03-31 |
$0.01B |
$-0.09B |
-1175.00% |
2021-12-31 |
$0.01B |
$-0.08B |
-1025.00% |
2021-09-30 |
$0.01B |
$-0.08B |
-987.50% |
2021-06-30 |
$0.01B |
$-0.08B |
-709.09% |
2021-03-31 |
$0.01B |
$-0.08B |
-576.92% |
2020-12-31 |
$0.01B |
$-0.08B |
-584.62% |
2020-06-30 |
$0.01B |
$-0.06B |
-1140.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.452B |
$0.007B |
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
|